Samin Houshyar

EE251 COST-SAVINGS ASSOCIATED WITH VENETOCLAX-OBINUTUZUMAB VERSUS COVALENT BRUTON’S TYROSINE KINASE INHIBITOR IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY

Alan P. Skarbnik, Nnadozie Emechebe, Bita Fakhri, Samin Houshyar et autres

us (code pays fourni par la source)

Data from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma

Edward R. Scheffer Cliff, Guido D. Pelaez, Fei Wan, Varun Iyengar et autres

AbstractPurpose: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than …

Supplemental Table 1 from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma

Edward R. Scheffer Cliff, Guido D. Pelaez, Fei Wan, Varun Iyengar et autres

Supplemental Table 1

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Ajay Major, Diana Abbott, Jordan Snyder, Nausheen Ahmed et autres

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time toxicity,” or contact days spent physically interacting with the healthcare system. …

us (code pays fourni par la source)

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Christopher E. Jensen, Mazyar Shadman, Andrés Chang, Nicole Lamanna et autres

Abstract Background Venetoclax (VEN)+obinutuzumab (VO) is an effective therapy for CLL/SLL requiring regular monitoring for tumor lysis syndrome (TLS) during VEN ramp-up. The CLL14 trial of VO reported no TLS during VEN ramp-up; however, there are limited real-world data on monitoring practices …

us, Afrique du Sud, gb, ch, ca (code pays fourni par la source)

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma

Edward R. Scheffer Cliff, Guido D. Pelaez, Fei Wan, Varun Iyengar et autres

PURPOSE: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than …

us, au, cn, nl (code pays fourni par la source)

ABCL-1335: A Retrospective Study of Patient Outcomes With Secondary CNS Lymphoma Receiving Novel Agents

Samin Houshyar, Tina Faugh, Paul M. Barr, Jonathan W. Friedberg et autres

us (code pays fourni par la source)

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Edward R. Scheffer Cliff, Fei Wan, Varun Iyengar, Jihao Zhou et autres

Background: Polatuzumab vedotin (Pola) is an antibody drug conjugate targeting CD79b that incorporates the microtubule disrupting monomethyl auristatin E payload. Pola was approved in 2023 for the upfront treatment of diffuse large B cell lymphoma (DLBCL) in combination with rituximab, cyclophosphamide, doxorubicin, …

us (code pays fourni par la source)

Effect of timing of recurrence on outcomes in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

Sujan Niraula, Diego Villamarin, Tae C. Smith, Ramandeep K. Babbra et autres

e13067 Background: CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) comprise the standard 1st line treatment for ER+ HER2- metastatic breast cancer (MBC). However, there is a gap in understanding how timing of MBC recurrence affects clinical outcomes on CDKi. We conducted a …

us (code pays fourni par la source)

A Phase Ib Study of the Safety and Efficacy of Venetoclax When Combined with Escalating Doses of Omacetaxine in Patients with Relapsed/Refractory Acute Myeloid Leukemia Failing Treatment with Venetoclax-Containing Regimens (VEN-OM)

Ana Maria Heuminski de Ávila, Saad Arain, Karen Sweiss, Pritesh Patel et autres

Background: Venetoclax (VEN) combined with hypomethylating agents (HMA) are increasingly used as first line (1L) treatment in AML patients (pt) intolerant of intensive chemotherapy, due to the high complete remission (CR) rate (66.4%), tolerance of therapy and a median duration CR of …

us (code pays fourni par la source)

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Samin Houshyar, Betül Gök Yavuz, Pritesh Patel, Nadim Mahmud et autres

Background: Omacetaxine mepesuccinate (OM), a semi-synthetic form of homoharringtonine (HHT), mechanistically inhibits aminoacyl-tRNA binding to ribosomal acceptor "A” sites, preventing mRNA translation (Wetzler,Curr Pharm Des 2011, 17:59-64), and causing a rapid decline of short-lived proteins e.g., c-myc, cyclin D, the anti-apoptotic proteins …

us (code pays fourni par la source)